Whether your patients are insured, uninsured, or underinsured, the Advancing Access program will work to help connect your patients to appropriate financial assistance.
If eligible, Advancing Access is available to help your patients:
*See specific terms and conditions at: www.GileadAdvancingAccess.com.
The Advancing Access program is committed to providing information for you and your patients to help address insurance and coverage issues should they arise.
Advancing Access can help your patients with:
Enroll your patient at GileadAdvancingAccess.com by downloading and completing the enrollment form today.
Hours: Monday – Friday, 9am to 8pm ET
BOXED WARNING: LACTIC ACIDOSIS/SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B
ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in patients 12 years and older who have no antiretroviral (ARV) treatment history with HIV-1 RNA ≤100,000 copies/mL; or to replace a stable ARV regimen in patients who are virologically-suppressed (HIV-1 RNA <50 copies/mL) for ≥6 months with no history of treatment failure and no known resistance to any component of ODEFSEY.
By following this link, you are leaving www.odefsey.com/hcp for a site that is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site’s content or your use of the site.
By following this link, you are leaving www.odefsey.com/hcp